<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35430383</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-0852</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>168</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>European journal of cancer (Oxford, England : 1990)</Title>
          <ISOAbbreviation>Eur J Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Predicting 10-year survival after resection of colorectal liver metastases; an international study including biomarkers and perioperative treatment.</ArticleTitle>
        <Pagination>
          <StartPage>25</StartPage>
          <EndPage>33</EndPage>
          <MedlinePgn>25-33</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejca.2022.01.012</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0959-8049(22)00033-8</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The aim of this study was to develop a prediction model for 10-year overall survival (OS) after resection of colorectal liver metastasis (CRLM) based on patient, tumour and treatment characteristics.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Consecutive patients after complete resection of CRLM were included from two centres (1992-2019). A prediction model providing 10-year OS probabilities was developed using Cox regression analysis, including KRAS, BRAF and histopathological growth patterns. Discrimination and calibration were assessed using cross-validation. A web-based calculator was built to predict individual 10-year OS probabilities.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 4112 patients were included. The estimated 10-year OS was 30% (95% CI 29-32). Fifteen patient, tumour and treatment characteristics were independent prognostic factors for 10-year OS; age, gender, location and nodal status of the primary tumour, disease-free interval, number and diameter of CRLM, preoperative CEA, resection margin, extrahepatic disease, KRAS and BRAF mutation status, histopathological growth patterns, perioperative systemic chemotherapy and hepatic arterial infusion pump chemotherapy. The discrimination at 10-years was 0.73 for both centres. A simplified risk score identified four risk groups with a 10-year OS of 57%, 38%, 24%, and 12%.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Ten-year OS after resection of CRLM is best predicted with a model including 15 patient, tumour, and treatment characteristics. The web-based calculator can be used to inform patients. This model serves as a benchmark to determine the prognostic value of novel biomarkers.</AbstractText>
          <CopyrightInformation>Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Buisman</LastName>
            <ForeName>Florian E</ForeName>
            <Initials>FE</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Erasmus MC Cancer Institute, Erasmus University, Rotterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giardiello</LastName>
            <ForeName>Daniele</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, the Netherlands; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kemeny</LastName>
            <ForeName>Nancy E</ForeName>
            <Initials>NE</Initials>
            <AffiliationInfo>
              <Affiliation>Department Medical Oncology, Memorial Sloan Kettering Cancer Centre, New York, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Steyerberg</LastName>
            <ForeName>Ewout W</ForeName>
            <Initials>EW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, the Netherlands; Department of Public Health, Erasmus MC, PO Box 20400, 3000 CA Rotterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Höppener</LastName>
            <ForeName>Diederik J</ForeName>
            <Initials>DJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Erasmus MC Cancer Institute, Erasmus University, Rotterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Galjart</LastName>
            <ForeName>Boris</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Erasmus MC Cancer Institute, Erasmus University, Rotterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nierop</LastName>
            <ForeName>Pieter M H</ForeName>
            <Initials>PMH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Erasmus MC Cancer Institute, Erasmus University, Rotterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Balachandran</LastName>
            <ForeName>Vinod P</ForeName>
            <Initials>VP</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cercek</LastName>
            <ForeName>Andrea</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department Medical Oncology, Memorial Sloan Kettering Cancer Centre, New York, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Drebin</LastName>
            <ForeName>Jeffrey A</ForeName>
            <Initials>JA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gönen</LastName>
            <ForeName>Mithat</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jarnagin</LastName>
            <ForeName>William R</ForeName>
            <Initials>WR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kingham</LastName>
            <ForeName>T P</ForeName>
            <Initials>TP</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vermeulen</LastName>
            <ForeName>Peter B</ForeName>
            <Initials>PB</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Cancer Research Unit (GZA Hospitals and University of Antwerp), Antwerp, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Alice C</ForeName>
            <Initials>AC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grünhagen</LastName>
            <ForeName>Dirk J</ForeName>
            <Initials>DJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Erasmus MC Cancer Institute, Erasmus University, Rotterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Verhoef</LastName>
            <ForeName>Cornelis</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Erasmus MC Cancer Institute, Erasmus University, Rotterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>D'Angelica</LastName>
            <ForeName>Micheal I</ForeName>
            <Initials>MI</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Koerkamp</LastName>
            <ForeName>Bas Groot</ForeName>
            <Initials>BG</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Erasmus MC Cancer Institute, Erasmus University, Rotterdam, the Netherlands. Electronic address: b.grootkoerkamp@erasmusmc.nl.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P30 CA008748</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Eur J Cancer</MedlineTA>
        <NlmUniqueID>9005373</NlmUniqueID>
        <ISSNLinking>0959-8049</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D048493">Proto-Oncogene Proteins B-raf</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.5.2</RegistryNumber>
          <NameOfSubstance UI="D016283">Proto-Oncogene Proteins p21(ras)</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006498" MajorTopicYN="N">Hepatectomy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008113" MajorTopicYN="Y">Liver Neoplasms</DescriptorName>
          <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048493" MajorTopicYN="N">Proto-Oncogene Proteins B-raf</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016283" MajorTopicYN="N">Proto-Oncogene Proteins p21(ras)</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Biomarkers</Keyword>
        <Keyword MajorTopicYN="N">Colorectal liver metastases</Keyword>
        <Keyword MajorTopicYN="N">Prediction</Keyword>
        <Keyword MajorTopicYN="N">Prognostic factors</Keyword>
      </KeywordList>
      <CoiStatement>Conflict of interest statement The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr Groot Koerkamp received pumps for intra-arterial chemotherapy for use in clinical trials from Tricumed.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2023</Year>
          <Month>6</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>17</Day>
          <Hour>20</Hour>
          <Minute>18</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35430383</ArticleId>
        <ArticleId IdType="mid">NIHMS1803054</ArticleId>
        <ArticleId IdType="pmc">PMC9117473</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ejca.2022.01.012</ArticleId>
        <ArticleId IdType="pii">S0959-8049(22)00033-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, et al.
Actual 10-year survival after resection of colorectal liver metastases defines cure. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007;25(29):4575–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17925551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Creasy JM, Sadot E, Koerkamp BG, Chou JF, Gonen M, Kemeny NE, et al.
Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure?
Surgery. 2018;163(6):1238–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7439273</ArticleId>
            <ArticleId IdType="pubmed">29455841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abbas S, Lam V, Hollands M. Ten-year survival after liver resection for colorectal metastases: systematic review and meta-analysis. ISRN Oncol. 2011;2011:763245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3200144</ArticleId>
            <ArticleId IdType="pubmed">22091431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kulik U, Plohmann-Meyer M, Gwiasda J, Kolb J, Meyer D, Kaltenborn A, et al.
Proposal of Two Prognostic Models for the Prediction of 10-Year Survival after Liver Resection for Colorectal Metastases. HPB Surg. 2018;2018:5618581.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6215566</ArticleId>
            <ArticleId IdType="pubmed">30420795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cucchetti A, Ferrero A, Cescon M, Donadon M, Russolillo N, Ercolani G, et al.
Cure model survival analysis after hepatic resection for colorectal liver metastases. Annals of surgical oncology. 2015;22(6):1908–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25398280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanas GP, Taylor A, Primrose JN, Langeberg WJ, Kelsh MA, Mowat FS, et al.
Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol. 2012;4:283–301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3496330</ArticleId>
            <ArticleId IdType="pubmed">23152705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galjart B, van der Stok EP, Rothbarth J, Grunhagen DJ, Verhoef C. Posttreatment Surveillance in Patients with Prolonged Disease-Free Survival After Resection of Colorectal Liver Metastasis. Annals of surgical oncology. 2016;23(12):3999–4007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5047936</ArticleId>
            <ArticleId IdType="pubmed">27393572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Margonis GA, Sasaki K, Gholami S, Kim Y, Andreatos N, Rezaee N, et al.
Genetic And Morphological Evaluation (GAME) score for patients with colorectal liver metastases. Br J Surg. 2018.</Citation>
        </Reference>
        <Reference>
          <Citation>Galjart B, Nierop PMH, van der Stok EP, van den Braak R, Hoppener DJ, Daelemans S, et al.
Angiogenic desmoplastic histopathological growth pattern as a prognostic marker of good outcome in patients with colorectal liver metastases. Angiogenesis. 2019;22(2):355–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6475515</ArticleId>
            <ArticleId IdType="pubmed">30637550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Höppener DJ, Galjart B, Nierop PMH, Buisman FE, van der Stok EP, Coebergh van den Braak RRJ, et al.
Histopathological Growth Patterns and Survival After Resection of Colorectal Liver Metastasis: An External Validation Study. JNCI Cancer Spectr. 2021;5(3):pkab026.</Citation>
        </Reference>
        <Reference>
          <Citation>Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al.
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371(9617):1007–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2277487</ArticleId>
            <ArticleId IdType="pubmed">18358928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Primrose J, Falk S, Finch-Jones M, Valle J, O’Reilly D, Siriwardena A, et al.
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. The Lancet Oncology. 2014;15(6):601–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24717919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kemeny N, Huang Y, Cohen AM, Shi W, Conti JA, Brennan MF, et al.
Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. The New England journal of medicine. 1999;341(27):2039–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10615075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ayez N, van der Stok EP, de Wilt H, Radema SA, van Hillegersberg R, Roumen RM, et al.
Neoadjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial. BMC cancer. 2015;15:180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4377036</ArticleId>
            <ArticleId IdType="pubmed">25884448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Groot Koerkamp B, Sadot E, Kemeny NE, Gonen M, Leal JN, Allen PJ, et al.
Perioperative Hepatic Arterial Infusion Pump Chemotherapy Is Associated With Longer Survival After Resection of Colorectal Liver Metastases: A Propensity Score Analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017:JCO2016718346.</Citation>
        </Reference>
        <Reference>
          <Citation>Rahbari NN, Reissfelder C, Schulze-Bergkamen H, Jager D, Buchler MW, Weitz J, et al.
Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy. BMC cancer. 2014;14:174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4008001</ArticleId>
            <ArticleId IdType="pubmed">24612620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al.
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): Long-term results of a randomised, controlled, phase 3 trial. The Lancet Oncology. 2013;14(12):1208–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24120480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kemeny NE, Gonen M. Hepatic arterial infusion after liver resection. The New England journal of medicine. 2005;352(7):734–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15716576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW, et al.
Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162(1):W1–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25560730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>  https://richtlijnendatabase.nl/richtlijn/colorectaal_carcinoom_crc/startpagina_-_crc.html.</Citation>
        </Reference>
        <Reference>
          <Citation>Power DG, Kemeny NE. The role of floxuridine in metastatic liver disease. Mol Cancer Ther. 2009;8(5):1015–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19383854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buisman FE, Grunhagen DJ, Homs MYV, Grootscholten C, Filipe WF, Kemeny NE, et al.
Adjuvant Hepatic Arterial Infusion Pump Chemotherapy After Resection of Colorectal Liver Metastases: Results of a Safety and Feasibility Study in The Netherlands. Annals of surgical oncology. 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>van Dam PJ, van der Stok EP, Teuwen LA, Van den Eynden GG, Illemann M, Frentzas S, et al.
International consensus guidelines for scoring the histopathological growth patterns of liver metastasis. Br J Cancer. 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Buisman F, van der Stok E, Galjart B, Vermeulen P, Allen P, Balanchandran V, et al.
Histopathological growth patterns as a guide for adjuvant systemic chemotherapy in patients with resected colorectal liver metastases. European Journal of Surgical Oncology. 2019;45(2):e10.</Citation>
        </Reference>
        <Reference>
          <Citation>Resche-Rigon M, White IR, Bartlett JW, Peters SA, Thompson SG, Group P-IS. Multiple imputation for handling systematically missing confounders in meta-analysis of individual participant data. Stat Med. 2013;32(28):4890–905.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23857554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>C DR. Regression Models and Life-Tables. Journal of the Royal Statiscial Society. 1972;34(2):187–220.</Citation>
        </Reference>
        <Reference>
          <Citation>Harrel FE. Regression Modeling Strategies: with applications to linear models, logistic and ordinal regression, and survival analysis: Springer; 2015.</Citation>
        </Reference>
        <Reference>
          <Citation>S. EW
Clinical prediciton models: a practical approach to developmentm validation and updating. New York: Springer; 2010.</Citation>
        </Reference>
        <Reference>
          <Citation>Steyerberg EW, Harrell FE Jr. Prediction models need appropriate internal, internal-external, and external validation. J Clin Epidemiol. 2016;69:245–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5578404</ArticleId>
            <ArticleId IdType="pubmed">25981519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Austin PC, Harrell FE Jr., van Klaveren D. Graphical calibration curves and the integrated calibration index (ICI) for survival models. Stat Med. 2020;39(21):2714–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7497089</ArticleId>
            <ArticleId IdType="pubmed">32548928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Annals of surgery. 1999;230(3):309–18; discussion 18–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1420876</ArticleId>
            <ArticleId IdType="pubmed">10493478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sullivan LM, Massaro JM, D’Agostino RB Sr. Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Stat Med. 2004;23(10):1631–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15122742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Konopke R, Kersting S, Distler M, Dietrich J, Gastmeier J, Heller A, et al.
Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases. Liver Int. 2009;29(1):89–102.</Citation>
        </Reference>
        <Reference>
          <Citation>Rees M, Tekkis PP, Welsh FK, O’Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Annals of surgery. 2008;247(1):125–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18156932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beppu T, Sakamoto Y, Hasegawa K, Honda G, Tanaka K, Kotera Y, et al.
A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection: multicenter data collection as a Project Study for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 2012;19(1):72–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22020927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iwatsuki S, Dvorchik I, Madariaga JR, Marsh JW, Dodson F, Bonham AC, et al.
Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. Journal of the American College of Surgeons. 1999;189(3):291–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2967754</ArticleId>
            <ArticleId IdType="pubmed">10472930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu W, Wang K, Han Y, Liang JY, Li YH, Xing BC. Nomogram predicted disease free survival for colorectal liver metastasis patients with preoperative chemotherapy followed by hepatic resection. Eur J Surg Oncol. 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Kanemitsu Y, Kato T. Prognostic models for predicting death after hepatectomy in individuals with hepatic metastases from colorectal cancer. World J Surg. 2008;32(6):1097–107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18200429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts KJ, White A, Cockbain A, Hodson J, Hidalgo E, Toogood GJ, et al.
Performance of prognostic scores in predicting long-term outcome following resection of colorectal liver metastases. Br J Surg. 2014;101(7):856–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24817653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zakaria S, Donohue JH, Que FG, Farnell MB, Schleck CD, Ilstrup DM, et al.
Hepatic resection for colorectal metastases: value for risk scoring systems?
Annals of surgery. 2007;246(2):183–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1933577</ArticleId>
            <ArticleId IdType="pubmed">17667495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reddy SK, Kattan MW, Yu C, Ceppa EP, de la Fuente SG, Fong Y, et al.
Evaluation of perioperative chemotherapy using a prognostic nomogram for survival after resection of colorectal liver metastases. HPB (Oxford). 2009;11(7):592–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2785955</ArticleId>
            <ArticleId IdType="pubmed">20495712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Margonis GA, Amini N, Buettner S, Kim Y, Wang J, Andreatos N, et al.
The Prognostic Impact of Primary Tumor Site Differs According to the KRAS Mutational Status: A Study By the International Genetic Consortium for Colorectal Liver Metastasis. Annals of surgery. 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Brudvik KW, Kopetz SE, Li L, Conrad C, Aloia TA, Vauthey JN. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg. 2015;102(10):1175–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26206254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gholami S, Kemeny NE, Boucher TM, Gonen M, Cercek A, Kingham TP, et al.
Adjuvant Hepatic Artery Infusion Chemotherapy is Associated With Improved Survival Regardless of KRAS Mutation Status in Patients With Resected Colorectal Liver Metastases: A Retrospective Analysis of 674 Patients. Annals of surgery. 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Goffredo P, Utria AF, Beck AC, Chun YS, Howe JR, Weigel RJ, et al.
The Prognostic Impact of KRAS Mutation in Patients Having Curative Resection of Synchronous Colorectal Liver Metastases. J Gastrointest Surg. 2018.</Citation>
        </Reference>
        <Reference>
          <Citation>Nierop PMH, Galjart B, Hoppener DJ, van der Stok EP, Coebergh van den Braak RRJ, Vermeulen PB, et al.
Salvage treatment for recurrences after first resection of colorectal liver metastases: the impact of histopathological growth patterns. Clin Exp Metastasis. 2019;36(2):109–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6445820</ArticleId>
            <ArticleId IdType="pubmed">30843120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nierop PMH, Hoppener DJ, van der Stok EP, Galjart B, Buisman FE, Balachandran VP, et al.
Histopathological growth patterns and positive margins after resection of colorectal liver metastases. HPB (Oxford). 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Ychou M, Hohenberger W, Thezenas S, Navarro M, Maurel J, Bokemeyer C, et al.
A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2009;20(12):1964–70.</Citation>
        </Reference>
        <Reference>
          <Citation>Kemeny NE, Chou JF, Boucher TM, Capanu M, DeMatteo RP, Jarnagin WR, et al.
Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy. J Surg Oncol. 2016.</Citation>
        </Reference>
        <Reference>
          <Citation>Buisman FE, Homs MYV, Grunhagen DJ, Filipe WF, Bennink RJ, Besselink MGH, et al.
Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases - the multicenter randomized controlled PUMP trial. BMC cancer. 2019;19(1):327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6451273</ArticleId>
            <ArticleId IdType="pubmed">30953467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Margonis GA, Buettner S, Andreatos N, Kim Y, Wagner D, Sasaki K, et al.
Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer. JAMA Surg. 2018;153(7):e180996.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6137519</ArticleId>
            <ArticleId IdType="pubmed">29799910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gagnière J, Dupré A, Gholami SS, Pezet D, Boerner T, Gönen M, et al.
Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?: A Multi-institutional Analysis of 1497 Patients. Annals of surgery. 2020;271(1):147–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29995686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steyerberg EW. Clinical prediction models: A practical approach to development, validation, and updating (statistics for biology and health)
Springer. New York. 2009.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
